Semaglutide Shows Major BMI Reductions in Young Children

Childhood obesity poses an escalating neurometabolic challenge across global populations, including in India. Currently, pediatricians possess very few medical interventions that offer durable efficacy. Consequently, the search for pharmacotherapy has intensified. The Phase 3 STEP Young clinical trial examined semaglutide for childhood obesity in patients aged 6 to under 12 years. This landmark investigation provides critical clinical insights into weight management during middle childhood.
STEP Young Study Design and Demographics
Specifically, investigators enrolled 167 children between the ages of 6 and 11 years across multiple global sites. Over 85% of these young participants suffered from class II or class III severe obesity at baseline. Researchers randomly assigned the children in a 2:1 ratio to receive either weekly subcutaneous semaglutide or a matching placebo. Furthermore, clinicians provided standardized lifestyle and dietary counseling to both treatment groups throughout the study. The maximum weekly semaglutide dose reached 2.4 mg for children above 60 kg and 1.7 mg for lighter participants. The active treatment phase continued for 104 full weeks, followed by a 7-week safety washout period.
Efficacy of Semaglutide for Childhood Obesity
The trial met its primary endpoint with high statistical significance. At week 68, semaglutide reduced mean body mass index by 13.5%. In contrast, children receiving placebo experienced a 2.7% increase in body mass index. This difference represented an estimated net benefit of 16.2 percentage points favoring semaglutide. Moreover, 79% of semaglutide-treated children reduced their overall obesity class, compared with only 23% in the placebo cohort. Remarkably, 38% of children on semaglutide dropped below the diagnostic obesity threshold of the 95th percentile. Sustained improvements persisted through week 104, confirming durable metabolic action.
Safety Profile and Pediatric Considerations
Overall, the safety profile matched observations previously seen in adolescent and adult populations. Most participants reported mild-to-moderate gastrointestinal adverse events, such as nausea and vomiting, primarily during dose escalation. However, clinicians observed a modest reduction in linear growth velocity during active therapy. Although height percentiles did not significantly shift, pediatricians must monitor skeletal maturation and pubertal milestones meticulously. In addition, healthcare providers must emphasize balanced pediatric nutrition to prevent micronutrient deficiencies during periods of reduced caloric intake. Therefore, comprehensive monitoring remains vital when utilizing pharmacotherapy in growing children.
Clinical Takeaways for Indian Physicians
Childhood obesity is rising sharply in urban Indian healthcare centers. Pediatricians frequently encounter children with early insulin resistance, hepatic steatosis, and hypertension. While lifestyle modification remains foundational, behavioural measures alone rarely overcome severe neurometabolic drivers of obesity. Consequently, potent GLP-1 receptor agonists offer a promising future therapeutic tool for refractory cases. Nevertheless, Indian clinicians should wait for regulatory clearance before considering off-label use in younger age groups. In practice, physicians should continue combining structured lifestyle interventions with rigorous clinical surveillance, supported by continuous learning through specialized paediatrics speciality courses.
Frequently Asked Questions
Q1: What did the STEP Young trial evaluate?
The trial evaluated the efficacy and safety of once-weekly subcutaneous semaglutide compared with placebo in children aged 6 to under 12 years with obesity.
Q2: How much did semaglutide reduce BMI in the study?
At week 68, semaglutide achieved a 13.5% reduction in mean body mass index, whereas placebo showed a 2.7% increase.
Q3: What were the most common side effects observed in children?
Gastrointestinal adverse effects, such as nausea, vomiting, and diarrhea, occurred most frequently, especially during the initial dose escalation phase.
References
- Jastreboff AM et al. Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age. N Engl J Med. 2026 Nov 16. doi: 10.1056/NEJMoa2604058. PMID: 43037562.
- Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245-2257.





